Duranest is developed by Astrazeneca.

What development phase is Duranest in?

Duranest is FDA-approved (marketed).

What is the generic name of Duranest?

ETIDOCAINE is the generic (nonproprietary) name of Duranest.

Last reviewed 2026-04-20 · How we verify

Duranest (ETIDOCAINE)

Astrazeneca · FDA-approved approved Small molecule Quality 20/100

Etidocaine (Duranest) is a marketed local anesthetic that blocks potassium channels to prevent pain signal transmission, competing in a crowded market with established drugs like bupivacaine and lidocaine. Its key strength lies in its unique mechanism of action through potassium channel blockade, distinguishing it from sodium channel blockers like bupivacaine and lidocaine. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	ETIDOCAINE
Sponsor	Astrazeneca
Drug class	etidocaine
Target	Potassium channel subfamily K member 3, Sodium channel protein type 2 subunit alpha, Sodium channel protein type 4 subunit alpha
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	FDA-approved
First approval	1976

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Duranest CI brief — competitive landscape report
Duranest updates RSS · CI watch RSS